Abstract
In vitro screening of 307 drugs with various clinical indications (cardiotropic, neurotropic, antibacterial, etc.) has revealed 6 compounds which displayed remarkable antiretroviral activity. Three of these drugs had a tendency to have undesirable side effects and were thus excluded from further consideration. Remaining three, i.e., Xantinol Nicotinate, Tardiferon, and Trental may become valid candidates for inclusion into antiviral regimens such as HAART. In vitro tests have shown that xantinol and trental display synergistic effect with azidothymidine, inhibit the replication AZT-resistant strains of HIV, and have no competing undesirable activities. These compounds should be evaluated in safety studies to determine optimal doses for patients with HIV. If these studies confirm in vitro results these compounds may become valid candidates as safe and affordable means to be added into the arsenal of antiretroviral drugs.
Keywords: Novel Inhibitors, HIV, Clinical Indications, antiretroviral activity, Xantinol Nicotinate, HAART
Current Pharmaceutical Design
Title: Novel Inhibitors of HIV Discovered Among Existing Classes of Pharmaceutical Compounds Indicated for Unrelated Clinical Indications
Volume: 15 Issue: 11
Author(s): I. I. Kucherov, P. G. Rytik, I. A. Podol'skaya, L. O. Mistryukova and M. O. Korjev
Affiliation:
Keywords: Novel Inhibitors, HIV, Clinical Indications, antiretroviral activity, Xantinol Nicotinate, HAART
Abstract: In vitro screening of 307 drugs with various clinical indications (cardiotropic, neurotropic, antibacterial, etc.) has revealed 6 compounds which displayed remarkable antiretroviral activity. Three of these drugs had a tendency to have undesirable side effects and were thus excluded from further consideration. Remaining three, i.e., Xantinol Nicotinate, Tardiferon, and Trental may become valid candidates for inclusion into antiviral regimens such as HAART. In vitro tests have shown that xantinol and trental display synergistic effect with azidothymidine, inhibit the replication AZT-resistant strains of HIV, and have no competing undesirable activities. These compounds should be evaluated in safety studies to determine optimal doses for patients with HIV. If these studies confirm in vitro results these compounds may become valid candidates as safe and affordable means to be added into the arsenal of antiretroviral drugs.
Export Options
About this article
Cite this article as:
Kucherov I. I., Rytik G. P., Podol'skaya A. I., Mistryukova O. L. and Korjev O. M., Novel Inhibitors of HIV Discovered Among Existing Classes of Pharmaceutical Compounds Indicated for Unrelated Clinical Indications, Current Pharmaceutical Design 2009; 15 (11) . https://dx.doi.org/10.2174/138161209787846856
DOI https://dx.doi.org/10.2174/138161209787846856 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial(Angiotensin II Receptor Research)
Current Pharmaceutical Design Vitamin D and Sepsis: From Associations to Causal Connections
Inflammation & Allergy - Drug Targets (Discontinued) New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Antithrombotic Therapy
Current Molecular Medicine Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Hemostatic Factors and the Metabolic Syndrome
Current Vascular Pharmacology Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Current Pharmaceutical Design Puerarin: A Review on the Pharmacological Activity, Chemical Properties and Pharmacokinetics of Main Isoflavonoid
The Natural Products Journal Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?
Current Vascular Pharmacology Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
Reviews on Recent Clinical Trials Impact of Different Soil Enrichments on the Physicochemical and Antioxidant Potential of Red and White Calyx from Roselle (Hibiscus sabdariffa L.)
Current Nutrition & Food Science State of the Heart: CMR in Coronary Artery Disease
Current Medical Imaging Insulin Resistance as a Proinflammatory State: Mechanisms, Mediators, and Therapeutic Interventions
Current Drug Targets Immune System Alterations by Aldosterone During Hypertension: From Clinical Observations to Genomic and Non-Genomic Mechanisms Leading to Vascular Damage
Current Molecular Medicine Nanoceuticals as an Emerging Field: Current Status and Future Prospective
Current Nutrition & Food Science Mechanical Circulatory Support for End-Stage Heart Failure in Repaired and Palliated Congenital Heart Disease
Current Cardiology Reviews Implications of Pharmacogenetics for Oral Anticoagulants Metabolism
Current Drug Metabolism